Abstract 2118P
Background
The refeeding syndrome is a potentially lethal condition, associated with metabolic alterations after food reintroduction, and subsequent increase in nutritional intake. It occurs especially in malnourished patients, or in a hyper-catabolic stage. Particularly oncological diseases represent an increased risk factor for the manifestation of the syndrome. Data related to the oncological population is rarely reported, except for the various case series/case studies published to date.This study aims to determine the prevalence of refeeding syndrome in oncological patients according to their risk and to develop a clinical pathway to address and monitor this syndrome.
Methods
A prospective longitudinal study was carried out on 124 patients who started exclusive support via parenteral or enteral nutrition, in 4 units of the oncology hospital: intensive care, intermediate care, medical and surgical inpatient units. Risk for refeeding syndrome was determined as follows: low risk, moderate, high. Biochemistry available (ionogram) before feeding, and its evolution over the first 5 days after initiation was evaluated.
Results
In 64% of patients, serum phosphate, potassium, and magnesium measurements were available prior to nutritional support. There was no information on serum phosphate in 29.7% of patients, with no significant differences between surgical and medical patients. After 48 hours, serum concentration variations were especially pronounced in patients without electrolyte supplementation prior to feeding (-18.2%) versus previously supplemented (10.3%) (p=0.035). After 72 hours, 31.8% of patients experienced reductions superior to 30% in the ionogram, compatible with refeeding syndrome. A positive Spearman's correlation (0.69, p=0.017) was identified between the initially assessed risk (moderate and high) and the decrease in phosphate (>20%) observed at the end of 48 hours in non-supplemented patients.
Conclusions
There is a high prevalence of refeeding syndrome in cancer patients. Monitoring should be continuous, including hypophosphatemia. By providing a multidisciplinary intervention and allowing the provision of micronutrients at the appropriate time, complications of the syndrome can be avoided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Português de Oncologia do Porto Francisco Gentil (IPO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06